The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension

Česká verzia

Authors: J. Widimský
Authors place of work: Klinika kardiologie IKEM Praha, přednosta prof. MUDr. Jan Kautzner, CSc., FESC
Published in the journal: Vnitř Lék 2009; 55(2): 123-130
Category: Reviews

Summary

Combination of drugs from different classes of antihypertensives provides an additional antihypertensive effect thus minimising the probability of adverse effects related to the dose of antihypertensive. Combination therapy is indicated for the following groups of hypertensive patients: (a) all hypertensive patients whose systolic blood pressure exceeds the target systolic blood pressure value by > 20 mm Hg, or whose diastolic blood pressure exceeds the target diastolic blood pressure value by > 10 mm Hg; (b) in patients with diabetes mellitus (because the target values are < 130/80 mm Hg); (c) patients with target organ damage; (d) patients with a kidney or cardiovascular disease (patients with IHD, patients after a cerebrovascular accident); (e) patients with overall cardiovascular risk according the SCORE ≥ 5%. The advantage of fixed combinations resides in the fact that they increase compliance with treatment by reducing the number of pills taken by the patients. A fixed combination of the ACE inhibitor perindopril and the calcium channel blocker amlodipine proves optimal as has been shown by the results of the ASCOT-BPLA study. The launch of the above combination on this market should therefore be welcome. The fixed combination of perindopril and amlodipine will be indicated for hypertensive patients with uncontrolled hypertension or cardiovascular risk factors. This fixed combination will also be ideal for patients with a higher risk of diabetes mellitus, i.e. patients with a higher fasting glycaemia, in patients with impaired glucose tolerance and in patients with the metabolic syndrome. We strongly believe that it will improve the control of hypertension in our hypertensive patients, and improve the cardioprotective and nephroprotective effect of hypertension therapy.

Key words:
combination of antihypertensives – fixed combination – perindopril – amlodipine – improvement of the control of hypertension and prognosis

Zdroje

1. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25: 1105–1187.

2. Widimský J, Sachová M, Souček M et al. Vysoká prevalence a špatná kontrola hypertenze v ordinacích praktických lékařů. Vnitř Lék 2005; 51: 1087–1095.

3. Sharma A, Wittobee AH, Kirch W et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004; 22: 479–486.

4. Widimský J, Souček M, Sachová M et al. Hypertenze a diabetes mellitus v ordinacích praktických lékařů. Výskyt hypertenze a její kontrola. Cor Vasa 2005; 47: 127–132.

5. Klungel OH, Stricker BHC, Paes AHP et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999; 30: 1312–1318.

6. Souček M. Hypertenzní pacient v ordinaci internistů a kardiologů. Ústní sdělení.

7. Sever PS. Blood pressure control for the hypertensive patient. What can we do better? Am J Hypertens 1997; 10: 128A–130A.

8. Widimský J jr, Cífková R, Špinar J et al za Českou společnost pro hypertenzi. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101–118.

9. Dahlöf B, Sever PS, Poulter NR et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 895–906.

10. Julius S, Kjeldsen SE, Weber M et al for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–1975.

12. Williams B, Lacy PS, Thorn SM et al. Differential impact of blood pressure‑lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–1225.

13. Poulter NR, Wedel H, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907–913.

14. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al for the INVEST Investigators. A calcium antagonist vs. a non‑calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.

15. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 2008; 24: 3543–3557.

16. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.

17. Nissen SE, Tuzcu EM, Libby P et al for the CAMELOT Study. A randomized controlled trial. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA 2004; 292: 2217–2225.

18. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin‑converting‑enzyme inhibitor, ramipril, on cardiovascular events in high‑risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

19. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

20. The PEACE Trial Investigators. Angiotensin‑converting‑enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068.

21. Brown MJ, Palmer ChR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long‑acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000: 256: 366–372.

22. Hansson L, Hedner Th, Lund-Johansen P et al for the Nordil Study Group: Randomised trial of effects of calcium antagonists compared with diuretics and beta‑blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365.

23. Wiener G, Linz W, Hatrik S et al. Angiotensin‑converting enzyme inhibition alter nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 1997; 30: 1183–1190.

24. Elliott WJ, Meyer PM. Incident diabetesin clinical trials of antihypertensive drugs: a net-work meta‑analysis. Lancet 2007; 369: 201–207.

25. Kjeldsen SE, Julius S, Mancia G et al for the VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high‑risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405–1412.

26. Widimský J et al. Hypertenze. Praha: Triton 2008: 705.

27. Haffner SM, Lahto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.

28. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta‑analysis. Am J Hypertens 2003; 16: 895–899.

29. Bertrand ME on behalf of the EUROPA Executive Committee. Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients – analysis from the EUROPA study. Předneseno na kongresu Evropské kardiologické společnosti Mnichov v září 2008.

30. Poli KA, Tofler GH, Larson MG et al. Association of blood pressure with fibrinolytic potential in the Framigham Offspring population. Circulation 2000; 101: 264–269.

31. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006; 19: 129–138.

32. Jadhav U. Evaluation of efficacy and tolerability of perindopril and amlodipine combination in the management of patients with moderate-to-severe hypertension in India. Poster presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, LA, May 14–17. J Clin Hypertens 2008 (abstract).

33. Zillich AJ, Garg J, Basu S et al. Thiazide diuretics, potassium, and the development of diabetes. A quantitative review. Hypertension 2006; 48: 219–224.

34. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed‑dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–2597.

35. Bakris G, Molitch M, Zhou Q et al. Reversal of diuretic associated impaired glucose tolerance and new‑onset diabetes: results of the STAR-LET study J Cardiometab Syndr 2008; 3: 18–24.

36. Jamerson K, Bakris GL, Dahlöf B et al for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates The ACCOMPLISH trial. Blood Pressure 2007; 16: 80–86.

37. Jamerson K, Weber MA, Bakris GL et al for the ACCOMPLISH Trial Investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High Risk Patients. N Engl J Med 2008; 359: 2417–2428.